Thrifted Thursday: Shemika Simmons
SAVANNAH, Ga. (WSAV) — February is Heart Health Month and today, and on Thrifted Thursday we're shining light on heart health.
Every 34 seconds, someone dies from heart disease in the U.S., making it the number one cause of death.
One out of three women will die of heart disease and heart attack hospitalizations among women under 55 have increased according to the American Heart Association.
Our resident thrift-ologist Sharon Simpson joins WSAV's Tina Tyus-Shaw with a styled guest, Shemika Simmons.
Shemika, who is in her 40's, experienced a heart attack just a few months ago.
On today's show, she takes us through what happened.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNN
an hour ago
- CNN
Why men with broken heart syndrome are more likely to die, according to experts
Get inspired by a weekly roundup on living well, made simple. Sign up for CNN's Life, But Better newsletter for information and tools designed to improve your well-being. A 59-year-old man arrived at the Peking University First Hospital in Beijing for a procedure when he started having severe chest pain and shortness of breath. Four months earlier, he had cancerous tumors removed from his bladder. Around his family, he tried his best to appear strong and avoided discussions of his health. Privately, his severe anxiety over the possibility of a cancer recurrence kept him awake at night. Doctors said the man was experiencing takotsubo cardiomyopathy — also known as broken heart syndrome, as documented in a 2021 case study. The rare stress-induced heart condition has been observed primarily in women, but a study published in the Journal of the American Heart Association in May found that the illness may be more deadly for the men who get it. Thought to be caused by extreme emotional or physical events — such as learning about the death of a loved one, winning the lottery or lifting a heavy sofa — takotsubo cardiomyopathy, or TC, occurs when the heart muscle is flooded with stress hormones, causing part of it to 'freeze' in place. As the heart struggles to properly pump blood, symptoms resemble those of a heart attack, including chest pain, heart palpitations and irregular heartbeat. The new study analyzed data from nearly 200,000 patients hospitalized for TC in the United States between 2016 and 2020. While women accounted for 83% of the cases, men were more than twice as likely to die from the condition — with a mortality rate of 11.2%. 'The differences between men and women are a very striking finding,' said study coauthor Dr. Mohammad Reza Movahed, a clinical professor of medicine at the University of Arizona in Tucson. 'It raises a new, interesting question that should really be studied.' Broken heart syndrome in men vs. women Similar to differences between men's and women's cardiovascular health more generally, the discrepancies in TC death rates are not well understood, Movahed said, especially because they counter trends in other heart diseases. It's widely theorized, however, that differences in hormone levels play a role. Stressful situations trigger the adrenal glands to release our fight-or-flight hormones, called catecholamines. They are meant to increase our blood pressure and raise our heart rate, but extreme levels can temporarily 'stun' cells in the heart's tissue, leading to TC, Movahed explained. Men are thought to produce more catecholamines during stressful situations compared with women, possibly leading men to present with more severe cases of TC, he suggested. Estrogen, a sex hormone produced at higher levels in women, may also have a protective effect on the cardiovascular system, making it easier to manage an extreme influx of catecholamines and reducing the risk of severe complications from TC, said Dr. Louis Vincent, a noninvasive-cardiology research fellow at the University of Miami, who coauthored a similar, multiyear study investigating discrepancies in men and women who had TC. Vincent was not involved in the new study. Beyond biological differences, social factors may play a role as well. 'Most (physicians) know about takotsubo, but they may think of it as a disease just affecting women, so the diagnosis might be overlooked in men,' said Dr. Deepak Bhatt, a cardiologist and the director of Mount Sinai Fuster Heart Hospital who was not involved in the study. 'With misdiagnosis, care is delayed, and that can sometimes lead to worse outcomes.' Men may also seek care at a later stage of illness, believing that their symptoms are manageable or may pass, said Dr. Alejandro Lemor, an assistant professor of interventional cardiology at the University of Mississippi Medical Center who was also not involved in the study. Deadly complications from TC include blood clots, stroke, cardiac arrest and heart failure, Lemor said. If the condition is caught early, medications can reduce the risk of having these complications, restore proper heart function and allow for full recovery within weeks, he added. Higher mortality rates in men need further study Movahed's team was able to factor for important variables like age, race, income, chronic lung disease, hypertension and diabetes in the findings. However, there was no patient data on other comorbid diseases, such as a history of stroke or the presence of a Covid-19 infection, Vincent said. Additionally, the new study included in-patient diagnostic data only for those hospitalized with TC, so those who received outpatient care or died later from complications outside the hospital were likely not counted in the analysis, Movahed noted. To establish a firmer explanation for the differences in mortality rates between men and women and further test treatment methods, a more detailed dataset would be needed, Vincent said. 'People should be aware in studies like this, we're presenting findings that are based on diagnostic codes, and we're not looking at patient procedures or lab results,' Vincent said. 'But it's powerful in the sense that it lets us look at large populations and look at trends. And I think that this trend of a higher mortality in men is worth taking a deeper look into.' Don't try to 'tough it out' Sudden, severe chest pain or shortness of breath should always be treated as a medical emergency, warned Bhatt, who is also a professor of cardiovascular medicine at the Icahn School of Medicine at Mount Sinai in New York City. 'It's not a time to tough it out at home or get on the internet to figure it out. … Don't try to track down your primary care provider. Call emergency services,' Bhatt said. 'Time matters. By winning those few hours, you could save yourself irreparable damage to your heart.' Symptoms following physical stressors — a common cause of TC in men — should not be ignored, Movahed said, especially preceding medical events such as asthma attacks, seizures or complications from drug use. And while TC is caused by sudden stress, Bhatt said that managing chronic stress with daily meditation or exercise can lead to better cardiovascular health overall while giving you routines to fall back on in unexpected situations.
Yahoo
an hour ago
- Yahoo
Virtual Care Firm Omada Health Leverages GLP-1 Trend For $150 Million NASDAQ Debut
Omada Health, Inc. (NASDAQ:OMDA) closed its first day of trading at $23 per share on Friday, a 21% jump from the IPO price of $19 per share. On Thursday, Omada Health priced its initial public offering of 7.9 million at $19/share. The company filed its initial prospectus in May and updated the document with an expected pricing range of $18 to $20 per share. The company raised $150 million in its IPO. Reuters reported Omada Health's valuation hit $1.28 billion. Omada's revenue increased 57% in the first quarter of 2025 to $55 million from $35.1 million a year earlier, according to its prospectus. For 2024, revenue rose 38% to $169.8 million from $122.8 million the previous company's net loss narrowed to $9.4 million in the first quarter from $19 million a year ago. Omada launched its initial virtual program in diabetes prevention and weight health in 2012. The company delivers virtual care between doctor visits, providing an engaging, personalized, and integrated experience for members designed to improve their health while delivering value for employers, health plans, health systems, pharmacy benefit managers (PBMs), and other entities that cover the cost of programs. According to its S-1 filing, the company had 2,000 customers and more than 679,000 members enrolled in one or more programs as of 31 March. Omada says it has supported more than 1 million members since its launch. The company expanded its virtual care programs to target prediabetes, hypertension, and musculoskeletal conditions. The company estimates that about 20 million people have benefits coverage for one or more Omada programs. According to the company's S-1 filing, this represents about 14% of the self-insured insurance market, 9% of the fully insured market, 1% of the Medicare Advantage market, and 1% of the PBM market. Wall Street Journal, citing President Wei-Li Shao, writes that Omada leadership sees the current moment as the perfect time for an IPO, as GLP-1 drugs such as Ozempic, Wegovy, and Mounjaro have sparked a renewed focus on health problems that can stem from obesity. GLP-1s are expected to be a significant tailwind as more employers are rolling out reimbursement plans for the drugs, CEO Sean Duffy told WSJ. Omada, which signs contracts with employers to offer as a benefit to their workers, aims to be a complementary service that helps patients navigate taking GLP-1s. Omada's IPO is the second digital health IPO in weeks following an extended drought for the industry. In May, digital physical therapy startup Hinge Health Inc. (NYSE:HNGE) debuted on the New York Stock Exchange. Hinge Health priced its IPO of 13.7 million shares at $32 per share. Price Action: OMDA stock is trading lower by 0.43% to $22.90 premarket at last check Monday. Read Next:Photo via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Virtual Care Firm Omada Health Leverages GLP-1 Trend For $150 Million NASDAQ Debut originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Business Wire
3 hours ago
- Business Wire
Evofem Biosciences' CEO Saundra Pelletier Joins Aditxt Board of Directors
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Aditxt, Inc. (Nasdaq: ADTX) ('Aditxt' or the 'Company'), a social innovation platform accelerating promising health innovations, today announced the appointment of Saundra Pelletier, CEO of Evofem Biosciences, Inc. (OTCPK: EVFM) ('Evofem'), to Aditxt's Board of Directors. 'We believe that Saundra's background as a CEO and entrepreneur, coupled with her deep industry expertise and knowledge, will complement our current Board well. We look forward to her contributions at this critical stage as we seek to execute our growth strategy for the overall business, transition Aditxt to a commercial stage company, and advance our plans to build a vertical focus on monitoring, prevention and treatment of conditions impacting women's lives,' said Amro Albanna, Chairman and CEO of Aditxt. Ms. Pelletier is an expert in women's health, with insight driven by both intensive consumer research and deep commercial experience in the global markets with products addressing women's health spanning every stage in their reproductive journey, from puberty to menopause. Her career in the pharmaceutical industry has spanned more than three decades, during which she has launched pharmaceutical brands worldwide and expanded indications for female healthcare brands in multiple countries. She is a published author, TEDx and keynote speaker, executive coach and staunch advocate for innovation in women's healthcare. During her 10-year tenure as Chief Executive Officer, President and Executive Director of Evofem Biosciences, Ms. Pelletier has led the company through its transition to the public market, the approval of PHEXXI ® (lactic acid, citric acid, and potassium bitartrate), the first and only hormone-free, on-demand prescription contraceptive vaginal gel, the acquisition of SOLOSEC® (secnidazole) 2 g oral granules, an oral antibiotic approved to treat bacterial vaginosis and trichomoniasis with just one dose, and four consecutive years of net sales growth. Prior to Evofem, Ms. Pelletier was Executive Director at Woman Care Global, an international nonprofit organization focused on creating sustainable supply chains to deliver reproductive healthcare products to women in developing countries. She started her career at G.D. Searle where during her eight year tenure she served in increasingly senior positions and ultimately as Global Franchise Leader. Ms. Pelletier is also a Director of Windtree Therapeutics, Inc. (Nasdaq: WINT), and serves as an Advisory Board Member for several non-profit organizations including CEOs Against Cancer, Girls Inc., and The Center for Community Solutions. About Aditxt, Inc. Aditxt, Inc. is a social innovation platform accelerating promising health innovations. Aditxt's ecosystem of research institutions, industry partners, and shareholders collaboratively drives their mission to "Make Promising Innovations Possible Together." The innovation platform is the cornerstone of Aditxt's strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that democratizes innovation, ensures every stakeholder's voice is heard and valued, and empowers collective progress. The Company currently operates two programs focused on immune health and precision health. Through the proposed acquisition of Evofem under the July 2024 Amended and Restated Merger Agreement between Evofem, Aditxt and Adifem, Inc., as amended (the 'A&R Merger Agreement'), Aditxt aims to introduce an additional program dedicated to women's health. The companies are working toward a targeted close in the second half of 2025. The closing of the transaction with Evofem is subject to several conditions, including but not limited to approval of the transaction by Evofem's shareholders and Aditxt raising sufficient capital to fund its obligations at closing. These obligations include cash payments of approximately $17 million for Evofem, which includes approximately $15.2 million required to satisfy Evofem's senior secured noteholder; should Aditxt fail to secure these funds, Evofem's senior secured noteholder is expected to seek to prevent the closing of the merger with Evofem. No assurance can be provided that all of the conditions to closing will be obtained or satisfied or that the transaction will ultimately close. For more information, please visit Follow Aditxt on: Aditxt™, Adimune™, ADI-100™, Pearsanta™, and Mitomic™ are trademarks of Aditxt, Inc. PHEXXI ® and SOLOSEC ® are registered trademarks of Evofem Biosciences, Inc. Forward-Looking Statements This press release includes "forward-looking statements," within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "achieving," 'advancing', "aim," 'are working to,' "believe," "completing," "continue," "could," "design," "estimate," "expect," "intend," "may," "might," "plan," "possible," "potential," "predict," "project," "seek," "should," "suggest," "strategy," "target," "will," "would," and similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include but are not limited to anticipated contributions of Ms. Pelletier as a director of Aditxt; expected growth of Aditxt; Aditxt's ability to successfully execute its mission to accelerate and monetize promising health innovations, and magnitude thereof; and Aditxt's ability to close the planned acquisition of Evofem, including to meet all closing conditions, and the timing thereof. You are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements are disclosed in each company's SEC filings, including Aditxt's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 21, 2025, and any subsequent Form 10-Q filings. All forward-looking statements are expressly qualified in their entirety by such factors. Aditxt undertakes no duty to update any forward-looking statement except as required by law.
